Neumirna Therapeutics – an RNA-focused biotech company developing next-generation therapeutics for neurological disorders – announced the first closing of its Series A funding round at €20 million. New investors Angelini Ventures and Invivo Partners co-led the funding, with significant participation from Neumirna’s seed investor, Innovestor’s Life Science Fund, and other investors.
Neumirna was launched to transform the treatment paradigms for challenging neurological conditions and is at the forefront of RNA therapeutics, harnessing the power of microRNAs (miRNAs) to provide disease-modifying drugs. And the company’s pioneering drug discovery platform enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson’s disease (PD).
Neumirna’s lead therapeutic candidate NMT.001 is an Antisense Oligonucleotide (ASO) therapy addressing DRE, which is a condition affecting millions of patients worldwide who remain underserved by current treatment options. And the preclinical studies show unprecedented efficacy in animal models of DRE, highlighting the potential of NMT.001 to improve patient outcomes and quality of life significantly. With the new funding, Neumirna is poised to expand its research and development, scale its platform, and drive NMT.001 through the next key stages of development. This funding round marks a significant moment for Neumirna as it advances toward its goal of delivering life-changing therapies to patients in need.
Luis Pareras and Thomas Thestrup have been appointed to the Board of Directors, joining Milla Koistinaho, from Innovestor’s Life Science Fund, and Dr. Henrik Klitgaard, Scientific co-Founder of Neumirna Therapeutics.
KEY QUOTES:
“As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders. By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field. With our strong focus on brain disorders and a commitment to advancing innovative treatments for epilepsy, we are excited to collaborate with Neumirna’s management team on this journey to develop transformative solutions for patients worldwide.”
– Thomas Thestrup, Senior Principal at Angelini Ventures
“Investing in Neumirna represents a unique opportunity to support a pioneering company in leveraging RNA technology to treat neurological diseases. As a neurosurgeon, I am deeply impressed by the innovative approach and the results of NMT.001. The possibility of offering a transformative solution for patients with refractory, drug-resistant epilepsy, a devastating condition, is tremendously encouraging.”
– Luis Pareras, Managing Partner at Invivo Partners
